PDCD1 and neoplasm: For example, the combination of 4-1BB (a T cell co-stimulatory molecule) agonism and PD-1 blockade decreased exhaustion and increased the effector function of tumor-infiltrating lymphocytes in CT-2A tumors, leading to vastly improved survival compared to each treatment in isolation [45].